Group 1 - The new drug directory will be implemented in the province starting January 1, 2026, aiming to enhance the multi-level medical security system and include more effective and new drugs in the coverage [1] - Traditional Chinese medicine pieces will be managed under Class A, while the personal out-of-pocket ratio for regular Class B drugs (excluding negotiated drugs) will generally not exceed 10% [1] - For negotiated drugs, the personal out-of-pocket ratio for cancer treatment Western medicines will be 20%, while other drugs will be determined by each planning area, with a maximum of 20% [1] Group 2 - The commercial insurance innovative drug directory will be updated alongside the medical insurance directory, with the management of drugs in this directory following the principles of negotiated drugs [2] - Drugs in the commercial insurance innovative drug directory will not be covered by the medical insurance fund and will not be included in the basic medical insurance self-payment rate indicators [2] - Local medical insurance departments will promote the development of inclusive commercial health insurance and support the design of new products based on the commercial insurance innovative drug directory [2]

Core Viewpoint - The notification outlines the strategies and measures for enhancing the basic medical insurance system for urban and rural residents in Shanxi Province for the year 2025, focusing on increasing financial support, improving insurance coverage, and ensuring effective management and service delivery [1][2][3]. Group 1: Funding and Financial Support - The per capita financial subsidy for residents' medical insurance will increase by 30 yuan, reaching 700 yuan in 2025, with the central government covering 60% to 80% of the costs depending on the county's classification [1]. - The personal payment standard for 2026 is set at 400 yuan per person per year, with local financial departments required to allocate sufficient funds by October 31 [1]. Group 2: Enhancing Comprehensive Insurance Capacity - The basic medical insurance will cover hospitalization and outpatient services, maintaining a payment ratio of around 70% for eligible expenses, and will include maternity medical expenses under outpatient coverage [2]. - The big illness insurance will be funded through basic medical insurance contributions, with a focus on maintaining a balance between funding and expenditure to prevent risks to the insurance fund [2]. Group 3: Strengthening Medical Assistance - The medical assistance program will continue to support low-income and poverty-stricken populations, with a subsidy standard of 280 yuan per person per year for those at risk of falling back into poverty [3]. - A multi-tiered medical security system will be promoted, encouraging the development of commercial health insurance and charitable donations to meet diverse public needs [3][4]. Group 4: Enrollment and Payment Management - The plan emphasizes universal coverage, targeting key demographics such as students and migrant populations, with specific policies for newborns and students in higher education [5]. - The enrollment period for residents will be from late October 2025 to February 25, 2026, with immediate benefits for those who pay by the end of 2025 [5]. Group 5: Improving Management and Service Levels - There will be a focus on budget management for the insurance fund, with measures to enhance the efficiency of payment processes and prevent fraudulent activities [6]. - The notification calls for improved collaboration among various departments to ensure effective implementation of medical insurance policies and to raise public awareness [7].

Group 1 - The National Healthcare Security Administration has announced the preliminary review list for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, highlighting CAR-T therapies as a focal point [1] - Among the seven CAR-T products that have been launched, five are applying for the commercial insurance innovative drug catalog, while three are simultaneously pushing for inclusion in the basic medical insurance [1] - The commercial insurance innovative drug catalog covers a wide range of rare disease medications, cell and gene therapies, and advanced tumor immunotherapies, indicating a shift in the competitive landscape of the industry [1] Group 2 - The commercial insurance innovative drug catalog aims to include drugs that are not yet eligible for the medical insurance catalog but possess high innovation and clinical value [1] - This initiative is seen as a crucial step in building a multi-tiered medical security system, allowing more high-value innovative drugs to enter the payment system earlier, alleviating short-term pressure on medical insurance funds [1] - Companies involved in cell therapy concepts listed on the A-share market include Chengda Pharmaceutical and Guanhao Biological [1]